Fundraising Fox

GLX Analytix

15 employees on LinkedIn · 1 known investors

GLX Analytix develops a blood test platform that measures glycocalyx fragments and uses AI/ML to create disease-specific biomarker signatures for diagnosing and monitoring brain diseases including neuropsychiatric, neurodegenerative, and autoimmune conditions. The company targets clinicians and healthcare providers seeking early detection and precision medicine insights for conditions like Parkinson's, multiple sclerosis, schizophrenia, and stroke.

AI & Machine LearningDigital HealthMedical Devices

Founders & leadership

BBrian
BrianFounder & CEO

Investors · 1

DigitalDx VenturesMenlo Park

In the news

GLX Analytix Announces Strategic Investment from Labcorp Venture Fund and Alzheimer’s Drug Discovery Foundation (ADDF)einpresswire.com · Oct 2024GLX Analytix Pioneering Integrating AI with New Biomarkers for Personalized Healthcare Adds Health Tech Experts to Boardeinpresswire.com · Sep 2024Danish Startup GLX Analytix Prepares for Commercialization With Seed Investment | 360Dx360dx.com · Jul 2022GLX Analytix Receives Funds from DigitalDx Ventures, Vaekstfonden & CBC Investment Group to Accelerate Growtheinpresswire.com · Jun 2022

Frequently asked questions

What does GLX Analytix do?
GLX Analytix develops a blood test platform that measures glycocalyx fragments and uses AI/ML to create disease-specific biomarker signatures for diagnosing and monitoring brain diseases including neuropsychiatric, neurodegenerative, and autoimmune conditions. The company targets clinicians and healthcare providers seeking early detection and precision medicine insights for conditions like Parkinson's, multiple sclerosis, schizophrenia, and stroke.
Who founded GLX Analytix?
GLX Analytix was founded by Brian.
Who are GLX Analytix's investors?
GLX Analytix's investors include DigitalDx Ventures.